Joyce van de Leemput

Dr. Joyce van de Leemput

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
JZJun-yi Zhu
Jun-yi Zhu
GWGuanglei Wang
Guanglei Wang
XHXiaohu Huang
Xiaohu Huang
HLHangnoh Lee
Hangnoh Lee
JLJin-Gu Lee
Jin-Gu Lee
ZHZhe Han
Zhe Han
SARS-CoV-2 infection causes COVID-19, a severe acute respiratory disease associated with cardiovascular complications including long-term outcomes. The presence of virus in cardiac tissue of patients with COVID-19 suggests this is a direct, rather than secondary, effect of infection. Here, by expressing individual SARS-CoV-2 proteins in the Drosophila heart, we demonstrate interaction of virus Nsp6 with host proteins of the MGA/MAX complex (MGA, PCGF6 and TFDP1). Complementing transcriptomic data from the fly heart reveal that this interaction blocks the antagonistic MGA/MAX complex, which shifts the balance towards MYC/MAX and activates glycolysis—with similar findings in mouse cardiomyocytes. Further, the Nsp6-induced glycolysis disrupts cardiac mitochondrial function, known to increase reactive oxygen species (ROS) in heart failure; this could explain COVID-19-associated cardiac pathology. Inhibiting the glycolysis pathway by 2-deoxy-D-glucose (2DG) treatment attenuates the Nsp6-induced cardiac phenotype in flies and mice. These findings point to glycolysis as a potential pharmacological target for treating COVID-19-associated heart failure.

25 March 2021 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
JZJun-yi Zhu
Jun-yi Zhu
JLJin-Gu Lee
Jin-Gu Lee
JLJoyce van de Leemput
Joyce van de Leemput
HLHangnoh Lee
Hangnoh Lee
ZHZhe Han
Zhe Han
Background: SARS-CoV-2 causes COVID-19 with a widely diverse disease profile that affects many different tissues. The mechanisms underlying its pathogenicity in host organisms remain unclear. Animal models for studying the pathogenicity of SARS-CoV-2 proteins are lacking.Methods: Using bioinformatic analysis, we found that 90% of the virus-host interactions involve human proteins conserved inDrosophila. Therefore, we generated a series of transgenic fly lines for individual SARS-CoV-2 genes, and used the Gal4-UAS system to express these viral genes inDrosophilato study their pathogenicity.Results: We found that the ubiquitous expression of Orf6, Nsp6 or Orf7a inDrosophilaled to reduced viability and tissue defects, including reduced trachea branching as well as muscle deficits resulting in a “held-up” wing phenotype and poor climbing ability. Furthermore, muscles in these flies showed dramatically reduced mitochondria. Since Orf6 was found to interact with nucleopore proteins XPO1, we tested Selinexor, a drug that inhibits XPO1, and found that it could attenuate the Orf6-induced lethality and tissue-specific phenotypes observed in flies.Conclusions: Our study establishedDrosophilaas a model for studying the function of SARS-CoV2 genes, identified Orf6 as a highly pathogenic protein in various tissues, and demonstrated the potential of Selinexor for inhibiting Orf6 toxicity using an in vivo animal model system.

1 September 2021 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
JLJoyce van de Leemput
Joyce van de Leemput
ZHZhe Han
Zhe Han
SARS-CoV-2 causes the COVID-19 pandemic responsible for millions of deaths globally. Even with effective vaccines, the SARS-CoV-2 virus will likely maintain a hold in the human population through gaps in efficacy and vaccination and arising new strains. Therefore, understanding how SARS-Cov-2 causes such wide-spread tissue damage and developing targeted pharmacological treatments will be critical in fighting this virus and preparing for future outbreaks. Herein, we summarize the progress made thus far by using in vitro or in vivo models to investigate individual SARS-CoV-2 proteins and their pathogenic mechanisms. We grouped the SARS-CoV-2 proteins into three categories: host-entry, self-acting and host-interacting. This review focuses on the self-acting and host-interacting SARS-CoV-2 proteins and summarizes current knowledge on how these proteins promote virus replication and disrupt host systems, as well as drugs that target these virus- and interacting host proteins. Many of these drugs are currently in clinical trials for the treatment of COVID-19. Future coronavirus outbreaks will mostly likely be caused by new virus strains that evade the vaccines through mutations in host-entry proteins. Therefore, study of individual self-acting and host-interacting SARS-CoV-2 proteins for targeted therapeutic interventions is not only essential for fighting COVID-19, but also valuable against future coronavirus outbreaks.

13 June 2021 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
JLJoyce van de Leemput
Joyce van de Leemput
ZHZhe Han
Zhe Han
The COVID-19 pandemic is having a tremendous impact on humanity. Although COVID-19 vaccines are showing promising results, they are not 100% effective and resistant mutant SARS-CoV-2 strains are on the rise. To successfully fight against SARS-CoV-2 and prepare for future coronavirus outbreaks, it is essential to understand SARS-CoV-2 protein functions, their host interactions, and how these processes convey pathogenicity at host tissue, organ and systemic levels. In vitro models are valuable but lack the physiological context of a whole organism. Current animal models for SARS-CoV-2 research are exclusively mammals, with the intrinsic limitations of long reproduction times, few progeny, ethical concerns and high maintenance costs. These limitations make them unsuitable for rapid functional investigations of virus proteins as well as genetic and pharmacological screens. Remarkably, 90% of the SARS-CoV-2 virus-host interacting proteins are conserved between Drosophila and humans. As a well-established model system for studying human diseases, the fruit fly offers a highly complementary alternative to current mammalian models for SARS-CoV-2 research, from investigating virus protein function to developing targeted drugs. Herein, we review Drosophila’s track record in studying human viruses and discuss the advantages and limitations of using fruit flies for SARS-CoV-2 research. We also review studies that already used Drosophila to investigate SARS-CoV-2 protein pathogenicity and their damaging effects in COVID-19 relevant tissues, as well as studies in which the fly was used as an efficient whole animal drug testing platform for targeted therapeutics against SARS-CoV-2 proteins or their host interacting pathways.

15 August 2023 in Development
Verified
Journal Article
Closed access
PDF file
XHXiaohu Huang
Xiaohu Huang
YFYulong Fu
Yulong Fu
HLHangnoh Lee
Hangnoh Lee
YZYunpo Zhao
Yunpo Zhao
WYWendy Yang
Wendy Yang
ZHZhe Han
Zhe Han
Drosophila is an important model for studying heart development and disease. Yet, single-cell transcriptomic data of its developing heart have not been performed. Here, we report single-cell profiling of the entire fly heart using ∼3000 Hand-GFP embryos collected at five consecutive developmental stages, ranging from bilateral migrating rows of cardiac progenitors to a fused heart tube. The data revealed six distinct cardiac cell types in the embryonic fly heart: cardioblasts, both Svp+ and Tin+ subtypes; and five types of pericardial cell (PC) that can be distinguished by four key transcription factors (Eve, Odd, Ct and Tin) and include the newly described end of the line PC. Notably, the embryonic fly heart combines transcriptional signatures of the mammalian first and second heart fields. Using unique markers for each heart cell type, we defined their number and location during heart development to build a comprehensive 3D cell map. These data provide a resource to track the expression of any gene in the developing fly heart, which can serve as a reference to study genetic perturbations and cardiac diseases.

1 April 2024 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
JZJun-yi Zhu
Jun-yi Zhu
JLJoyce van de Leemput
Joyce van de Leemput
ZHZhe Han
Zhe Han
Diabetes is a metabolic disorder characterized by high blood glucose levels and is a leading cause of kidney disease. Diabetic nephropathy has been attributed to dysfunctional mitochondria. However, many questions remain about the exact mechanism. The structure, function and molecular pathways are highly conserved between mammalian podocytes and Drosophila nephrocytes; therefore, we used flies on a high-sucrose diet to model type 2 diabetic nephropathy. The nephrocytes from flies on a high-sucrose diet showed a significant functional decline and decreased cell size, associated with a shortened lifespan. Structurally, the nephrocyte filtration structure, known as the slit diaphragm, was disorganized. At the cellular level, we found altered mitochondrial dynamics and dysfunctional mitochondria. Regulating mitochondrial dynamics by either genetic modification of the Pink1–Park (mammalian PINK1–PRKN) pathway or treatment with BGP-15, mitigated the mitochondrial defects and nephrocyte functional decline. These findings support a role for Pink1–Park-mediated mitophagy and associated control of mitochondrial dynamics in diabetic nephropathy, and demonstrate that targeting this pathway might provide therapeutic benefits for type 2 diabetic nephropathy.